Cargando…
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin
PURPOSE: Efavirenz-based combination antiretroviral therapy (cART) is associated with neuropsychiatric adverse events. We investigated the time to onset, duration, clinical implications, impact of pharmacogenetic variations, and anti-tuberculosis co-treatment on efavirenz-associated neuropsychiatric...
Autores principales: | Mugusi, Sabina, Ngaimisi, Eliford, Janabi, Mohammed, Mugusi, Ferdinand, Minzi, Omary, Aris, Eric, Bakari, Muhammad, Bertilsson, Leif, Burhenne, Juergen, Sandstrom, Eric, Aklillu, Eleni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182598/ https://www.ncbi.nlm.nih.gov/pubmed/30003275 http://dx.doi.org/10.1007/s00228-018-2499-0 |
Ejemplares similares
-
Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania
por: Mugusi, Sabina, et al.
Publicado: (2012) -
Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype
por: Kitabi, Eliford Ngaimisi, et al.
Publicado: (2018) -
Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations
por: Ngaimisi, Eliford, et al.
Publicado: (2013) -
Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations
por: Mugusi, Sabina, et al.
Publicado: (2020) -
N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians
por: Aklillu, Eleni, et al.
Publicado: (2018)